Incerti Carlo 4

What Happened Carlo Incerti, a director of Dyne Therapeutics, was granted a derivative award covering 35,152 shares on June 5, 2026. The Form 4 reports the acquisition price as $0.00 (a grant/award), so no cash was paid by the insider at grant. This is a compensation/award transaction — not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-05; Form 4 filed: 2026-06-09 (filed 4 days after the transaction).
• Transaction type/code: Grant/Award (A) — derivative instrument reported.
• Shares involved: 35,152 underlying shares; reported price $0.00 (total reported value $0).
• Shares owned after transaction: not disclosed in the provided details.
• Footnote: The option was granted June 5, 2026 and is scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the issuer’s 2027 Annual Meeting of Stockholders, subject to continued service.
• No 10b5‑1 plan, tax‑withholding sale, or immediate sale of shares is indicated in the provided data.

Context This was a standard director equity award (an option/derivative grant) intended as compensation and subject to a one‑year (or earlier meeting) vesting condition. Such grants are routine for board members and do not by themselves indicate that the insider is buying or selling stock for personal investment reasons. The filing date is later than the typical 2 business‑day Form 4 deadline, so it appears to have been submitted after the usual reporting window.